Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron (NASDAQ: REGN )'s flagship eye drug franchise, consisting of EYLEA HD and EYLEA, saw U.S. net sales increase 2% to ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up ...

Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our ...

Los Angeles Clippers star forward Kawhi Leonard has stepped away from the team in order to help members of his family who were forced to evacuate due to the Southern California wildfires ...

Riley Leonard's decision to transfer from Duke to Notre Dame following the 2023 season has paid off. Through 15 games as the starting quarterback for the Irish, Leonard has led his squad to a 14 ...

Ahead of that presentation, Leonard Schleifer, board co-chair, president and CEO of Regeneron, stated: “The Regeneron name is synonymous with innovation, brought to life through proprietary ...

One of Kawhi Leonard‘s defining traits as both a player and a person is his honesty. Though he speaks softly, it’s clear he remains acutely aware of his performance and the challenges he faces. After ...